BioXcel Therapeutics
BTAI
BTAI
49 hedge funds and large institutions have $1.89M invested in BioXcel Therapeutics in 2024 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 27 reducing their positions, and 29 closing their positions.
New
Increased
Maintained
Reduced
Closed
less ownership
Funds ownership: →
less funds holding
Funds holding: →
less call options, than puts
Call options by funds: $ | Put options by funds: $
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
85% less capital invested
Capital invested by funds: $12.5M → $1.89M (-$10.6M)
86% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 29
Holders
49
Holding in Top 10
–
Calls
$22K
Puts
$34K
Top Buyers
| 1 | +$141K | |
| 2 | +$79.2K | |
| 3 | +$31.3K | |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$19.1K |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$18.4K |
Top Sellers
| 1 | -$3.82M | |
| 2 | -$2.82M | |
| 3 | -$261K | |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
-$140K |
| 5 |
Goldman Sachs
New York
|
-$127K |